Literature DB >> 18343400

Immunological methods to quantify and characterize proteasome complexes: development and application.

Matthias Majetschak1, Luis T Sorell.   

Abstract

The ubiquitin-proteasome pathway plays major roles in all aspects of biology and contributes to various disease processes. Due to the lack of assays that permit proteasome quantification in crude cell extracts, its concentrations in health and disease states as well as the relationship between free 20S core particles (20S) and 26S proteasomes (26S) that consist of 20S singly or doubly capped with 19S regulator complexes (19S) are still largely unknown. Thus, we established a 20S ELISA for the detection of total 20S, and developed a specific 26S ELISA. The latter utilizes the ATP/Mg2+ requirement for 26S stability and shows no cross-reactivity with 20S. Both ELISAs demonstrate intra- and inter-assay variations between 4.9% and 9.4% and recoveries of 105%-109%. Initial application showed that maintenance of the physiological ATP concentration is essential for accurate 26S assessment. Measurements in erythrocyte and peripheral blood mononuclear cell (PBMNC) extracts revealed that the concentrations of 20S were 15-fold and of 26S 130-fold higher in PBMNCs, and suggested that the 26S is the physiological relevant form in PBMNCs (molar ratio 20S/26S 1.1+/-0.4), whereas free 20S is predominant in erythrocytes (molar ratio 20S/26S: 11.5+/-4.0). During storage of packed red blood cell units spontaneous 26S assembly was detectable while specific 26S enzyme activities decreased, indicating that these assays are useful to assess the dynamic interplay between the 20S and 19S. During 26S assay development we further observed that solid phase affinity immobilization (SPAI) of 26S enables quantification of its dissociation into 20S and 19S. Utilizing the SPAI-26S method in combination with the non-hydrolyzable analogue ATP[beta,gamma-NH] and Mg2+ depletion, we provided evidence that ATP binding without hydrolysis via a high affinity binding site (Kd 4-6 microM) as well as ATP binding with hydrolysis via a low affinity binding site that is virtually not saturable under physiological conditions is required to fully stabilize the 26S. Application of these immunological techniques is expected to facilitate proteasome analyses, and may help to better understand its roles in health and disease processes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343400     DOI: 10.1016/j.jim.2008.02.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation.

Authors:  Todd A Baker; Qing Geng; Jacqueline Romero; Maria M Picken; Richard L Gamelli; Matthias Majetschak
Journal:  Biochem Biophys Res Commun       Date:  2010-09-26       Impact factor: 3.575

2.  Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

Authors:  David R Jones; Christopher A Moskaluk; Heidi H Gillenwater; Gina R Petroni; Sandra G Burks; Jennifer Philips; Patrice K Rehm; Juan Olazagasti; Benjamin D Kozower; Yongde Bao
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

3.  Circulating proteasomes after burn injury.

Authors:  Matthias Majetschak; Siegfried Zedler; Jacqueline Romero; Joslyn M Albright; Robert Kraft; Elizabeth J Kovacs; Eugen Faist; Richard L Gamelli
Journal:  J Burn Care Res       Date:  2010 Mar-Apr       Impact factor: 1.845

4.  Proteasome Inhibition After Burn Injury.

Authors:  P Geoff Vana; Heather M LaPorte; Yee M Wong; Richard H Kennedy; Richard L Gamelli; Matthias Majetschak
Journal:  J Burn Care Res       Date:  2016 Jul-Aug       Impact factor: 1.845

5.  A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.

Authors:  Shinji Iwasaki; Andy Zhu; Michael Hanley; Karthik Venkatakrishnan; Cindy Xia
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

6.  Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus.

Authors:  Matthias Majetschak; Magdalena Perez; Luis T Sorell; Janet Lam; Marcos E Maldonado; Robert W Hoffman
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

7.  Circadian rhythm of hyperoxidized peroxiredoxin II is determined by hemoglobin autoxidation and the 20S proteasome in red blood cells.

Authors:  Chun-Seok Cho; Hyun Ju Yoon; Jeong Yeon Kim; Hyun Ae Woo; Sue Goo Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

8.  A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia.

Authors:  Qing Geng; Jacqueline Romero; Vikas Saini; Todd A Baker; Maria M Picken; Richard L Gamelli; Matthias Majetschak
Journal:  Biochem Biophys Res Commun       Date:  2009-12-25       Impact factor: 3.575

9.  Proteasomes in human bronchoalveolar lavage fluid after burn and inhalation injury.

Authors:  Joslyn M Albright; Jacqueline Romero; Vikas Saini; Stephan U Sixt; Melanie D Bird; Elizabeth J Kovacs; Richard L Gamelli; Jürgen Peters; Matthias Majetschak
Journal:  J Burn Care Res       Date:  2009 Nov-Dec       Impact factor: 1.845

10.  Activities of nonlysosomal proteolytic systems in skeletal and cardiac muscle during burn-induced hypermetabolism.

Authors:  Yee M Wong; Heather M La Porte; Andrea Szilagyi; Harold H Bach; Li Ke-He; Richard H Kennedy; Richard L Gamelli; Ravi Shankar; Matthias Majetschak
Journal:  J Burn Care Res       Date:  2014 Jul-Aug       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.